Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
Part of paid clinical trials in Richmond, Virginia.
- Sponsor
- Virginia Commonwealth University
- Study ID
- NCT06747884
- Status
- Recruiting
Conditions
- Childhood Myotonic Dystrophy
- Congenital Myotonic Dystrophy
- Myotonic Dystrophy
Eligibility Criteria
- Sex
- ALL
- Age
- 3 Years - 17 Years
- Healthy Volunteers
- Not accepted
Study Details
This is a natural history study to improve the types of assessments and biological samples that will be used in clinical drug trials in both congenital myotonic dystrophy and childhood myotonic dystrophy.
Key Dates
- Start date
- Jun 6, 2025
- Status verified
- Jul 2025
- Primary completion
- Jun 30, 2030
- Completion
- Jun 30, 2030
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: Congenital myotonic dystrophy (CDM)Children with congenital myotonic dystrophy. No intervention will be administered to either group.
- Arm: Childhood Myotonic DystrophyChildren with childhood myotonic dystrophy. No intervention will be administered to either group.
Primary Outcome Measure
Change in ambulation over 24 months as measured by the 10-Meter Walk/Run Test (10M WRT) [ Time Frame: Baseline, Month 12 and Month 24 visits ]
Central Contacts
- Ruby Langeslay, MPH804-828-6318
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Virginia Commonwealth University | Richmond | Virginia | 23298 | Levi Headrick Nicholas E Johnson, MD, MSCI, FAAN (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Richmond, VA
By research site
Related Studies
- Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic DystrophyPHASE2/PHASE3 · Recruiting · AMO Pharma Limited · Little Rock, Arkansas
- DMCRN-02-001: Assessing Pediatric Endpoints in DM1Recruiting · Virginia Commonwealth University · Los Angeles, California
- A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1PHASE1/PHASE2 · Recruiting · Sanofi · Gainesville, Florida
- Global Open-Label Extension Study of Del-desiran for the Treatment of DM1PHASE3 · Enrolling By Invitation · Avidity Biosciences, Inc. · Los Angeles, California